3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
54
Other hematologic neoplasm
26
Plasma cell
1
Myeloid
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Classical hematology
1
CNS
1
Conditions
Waldenstrom Macroglobulinemia
1
Multiple Myeloma
1
Interventions
Dexamethasone
124
daratumumab
73
Lenalidomide
72
Bortezomib
61
pomalidomide
45
Cyclophosphamide
41
carfilzomib
40
Calcium Dobesilate
36
Specimen Handling
34
Biopsy
30
Magnetic Resonance Spectroscopy
27
belantamab mafodotin
24
isatuximab
20
fludarabine
20
dexamethasone acetate
18
dexamethasone 21-phosphate
18
auricularum
18
Melphalan
18
talquetamab
16
iberdomide
16
fludarabine phosphate
12
selinexor
11
elotuzumab
10
X-Rays
10
tocilizumab
9
Nivolumab
8
Sirolimus
7
Crizotinib
7
trametinib
6
Whole-Body Irradiation
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
ibrutinib
×
Plasma cell
×
90 days
×
Clear all
NCT07474961
2026-03-16
BLOOD-dose
Rigshospitalet, Denmark
Phase 4
Not yet recruiting
400 enrolled